| Code | CSB-RA011087MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Teprotumumab-TRBW, designed to target the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a transmembrane tyrosine kinase receptor that mediates cellular responses to IGF1, regulating critical processes including cell proliferation, differentiation, survival, and metabolism. This receptor plays a significant role in various pathological conditions, particularly in oncogenesis where it promotes tumor growth and metastasis, and in thyroid eye disease where IGF1R overexpression on orbital fibroblasts contributes to tissue remodeling and inflammation.
Teprotumumab-TRBW represents the first FDA-approved treatment specifically for thyroid eye disease, functioning as an IGF1R antagonist that blocks receptor activation and downstream signaling pathways. This biosimilar antibody serves as a valuable research tool for investigating IGF1R-mediated signaling mechanisms, exploring the pathophysiology of thyroid-associated ophthalmopathy, and studying IGF1R involvement in cancer biology and metabolic disorders. It enables researchers to examine receptor blocking strategies and evaluate potential therapeutic interventions targeting the IGF1R pathway.
There are currently no reviews for this product.